GLP-1 Drugs & Colorectal Cancer Risk: Better Than Aspirin?

The landscape of colorectal cancer prevention may be on the verge of a significant shift. A new study presented at the 2026 ASCO Gastrointestinal Cancers Symposium suggests that GLP-1 receptor agonists (GLP-1s), a class of drugs already gaining widespread use for diabetes and obesity, demonstrate a substantial advantage over aspirin in preventing colorectal cancer – and with a potentially safer side effect profile. This finding arrives at a critical juncture, as the efficacy and bleeding risks associated with aspirin have long tempered its widespread adoption as a preventative measure.

The Shifting Paradigm in Colorectal Cancer Prevention

Colorectal cancer remains a significant public health concern, projected to affect approximately 154,270 Americans in 2025, with around 53,000 fatalities. For decades, low-dose aspirin has been investigated as a preventative strategy, leveraging its anti-inflammatory properties. However, the risk of bleeding complications has always been a major deterrent. The emergence of GLP-1RAs, initially developed to manage type 2 diabetes by enhancing insulin secretion and suppressing glucagon, presents a compelling alternative. Recent research has hinted at their potential anticancer effects, specifically through the inhibition of the P13K/Akt/mTOR pathway, a key regulator of cell growth and proliferation.

This large-scale, real-world study, utilizing data from over 280,000 individuals, provides the most robust evidence to date comparing these two approaches directly. The researchers meticulously matched cohorts of GLP-1RA users and aspirin users, controlling for demographics like age, gender, and race. The findings are striking: a 36% reduction in colorectal cancer incidence among those taking GLP-1RAs. This benefit climbed to nearly 42% for individuals with pre-existing risk factors. Importantly, the GLP-1RA cohort also experienced fewer instances of acute kidney injury, stomach ulcers, and gastrointestinal bleeding – side effects commonly associated with aspirin.

What to Watch: The Road Ahead

While these results are encouraging, several key questions remain. The study highlights that the benefit of GLP-1s, on an individual level, is relatively small, requiring treatment of over 2,000 people to prevent one case of colorectal cancer. However, given the increasing prevalence of GLP-1RA use – currently estimated at 6% of adults, potentially reaching 20 million Americans – the population-level impact could be substantial. The differential efficacy observed among various GLP-1RA medications (semaglutide, liraglutide, and dulaglutide showing significant effects, while tirzepatide and exenatide did not) warrants further investigation to understand the underlying mechanisms.

The study also revealed nuances regarding patient characteristics. GLP-1s demonstrated benefit even in individuals initiating treatment before age 45, and regardless of obesity or diabetes status. However, the protective effect was absent in those with a history of tobacco use or atherosclerotic disease, suggesting potential interactions or confounding factors.

The next crucial step is prospective validation through randomized clinical trials. As Dr. Colton Jones, the lead author, emphasized, the favorable safety profile of GLP-1RAs, coupled with these promising results, “could underscore a potential public health impact.” Expect to see a surge in research activity focused on GLP-1RAs as a preventative strategy for colorectal cancer, potentially leading to revised clinical guidelines and a broader discussion about the role of these medications beyond metabolic control. ASCO expert Dr. Joel Saltzman echoed this sentiment, highlighting the potential for GLP-1s to become an integral part of cancer prevention strategies. The coming years will be pivotal in determining whether this promising signal translates into a new standard of care.